Alphatec's compounding engine: 20% case growth and 24% surgeon adds drive a profitable quarter
The company raised EBITDA guidance and posted positive free cash flow, while EOS Insight strengthens its surgical pull-through.
ATEC · Earnings Call · 2026-08-04
The Quarter That Proves the Model
Alphatec Holdings (ATEC) delivered another strong quarter, with revenue up 15% to $214 million, surgical revenue up 17%, case volume up 20%, and surgeon adds up 24%. The company generated $36 million of adjusted EBITDA, a 17% margin, and positive free cash flow. Management's commentary reflects confidence in the compounding growth engine. “That's exactly the compounding engine we've been building. More surgeons, more cases, more platform pull-through, and now it's dropping to the bottom line, creating profitable growth.” — Patrick Miles, Chief Executive Officer · 2026-08-04 The growth is broad-based: case volume growth of 20% and surgeon user growth of 24% are leading indicators that add durability to the revenue trajectory. This follows the same pattern the company has highlighted in prior calls: surgeon additions consistently run ahead of revenue, providing a multi-year runway. As noted in the Q1 call, “The most comforting part is that momentum where we most distinguish continues to be profoundly robust. Surgeon additions up over 20% speaks to a business in demand.” — Patrick S. Miles, Chief Executive Officer · 2026-05-05EOS and the Pull-Through Advantage
EOS revenue reached $17 million in Q2, flat year-over-year but up from $14 million in Q1, with demand for systems remaining strong. More importantly, EOS Insight adoption continues to expand. Management highlighted that accounts with Insight see a 32% revenue lift within six months of go-live, driven by implants, patient-specific rods, and procedural adoption. This EOS thing is becoming a strategic moat, giving ATEC access to top academic institutions and training the next generation of spine surgeons. The company's ability to convert an imaging system into a surgical planning and execution platform is a unique asset in the spine market. As Patrick Miles noted in the October call when discussing the competitive landscape, “We love market disruption.” — Patrick Miles, Chief Executive Officer · 2025-10-30 That disruption is working in ATEC's favor.Revenue Per Case and Biologics: The Watch Items
While case growth is stellar, revenue per case declined 2.7% year-over-year, pressured by case mix (strong cervical and international growth) and a lower biologic attachment rate. Management attributed about three-quarters of the revenue-per-case shortfall to biologics, but noted that attachment stabilized in Q2. The company expects the year-over-year revenue per case decline to moderate in the second half and is investing in new products, including the TheraDaptive BMP program, to differentiate in biologics. As CFO Todd Koning explained, “Overall revenue per case declined approximately 2.7% year-over-year, driven by case mix and strong international growth. The remaining pressure was primarily attributable to biologics attachment, which stabilized in Q2 but remained below prior year levels.” — J. Koning, Chief Financial Officer · 2026-08-04 This theme of revenue per procedure has been a recurring focus for analysts; in the prior quarter, management guided to flattish revenue per procedure, but has now revised to a low-single-digit decline. The adjustment reflects a more conservative outlook on biologics improvement, though volume growth remains robust.Margins, Cash Flow, and Guidance
The company's operating leverage is undeniable. Gross margin expanded 260 basis points to 72.5%, driven by inventory efficiency, cost reductions, and product mix. Adjusted EBITDA margin rose 420 basis points to 17%, and the company raised its full-year EBITDA guidance to approximately $140 million (16% margin) from $134 million. Free cash flow turned positive in Q2, and the company expects $4-6 million in Q3 and at least $20 million for the full year. This is a notable inflection for a company that historically burned cash. The balance sheet also improved: a new term loan and revolver with JPMorgan and TD Cowen extended maturities to 2031 and will cut interest expense by over $6 million annually. Revenue has grown from $32 million in Q2 2016 to $214 million today, a 10x increase over eight years. The company is trading at approximately 2.1x forward revenue, reflecting both the growth expectations and the lingering concerns about revenue per case.The stock has been under pressure lately, down 13% over the past 90 days, but the underlying business is executing. The key question for investors is whether revenue per case can stabilize and whether biologics attachment returns to growth. With surgeon adoption at record levels and EOS contributing an increasing pull-through, the long-term algorithm appears intact.We are in this for the long haul. We are building ATEC for decades and beyond. This quarter showed we can continue to grow at multiples of the market and turn that growth into profitability and cash.